These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29285874)

  • 41. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy.
    Liu CL; Ye P; Yen BC; Miao CH
    Mol Ther; 2011 Aug; 19(8):1511-20. PubMed ID: 21468007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII.
    Sarkar R; Gao GP; Chirmule N; Tazelaar J; Kazazian HH
    Hum Gene Ther; 2000 Apr; 11(6):881-94. PubMed ID: 10779165
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Factor VIII with a 237 amino acid B-domain has an extended half-life in F8-knockout mice.
    Bloem E; Karpf DM; Nørby PL; Johansen PB; Loftager M; Rahbek-Nielsen H; Petersen HH; Blouse GE; Thim L; Kjalke M; Bolt G
    J Thromb Haemost; 2019 Feb; 17(2):350-360. PubMed ID: 30525289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.
    Jing W; Chen J; Cai Y; Chen Y; Schroeder JA; Johnson BD; Cui W; Shi Q
    Blood Adv; 2019 Oct; 3(20):3099-3110. PubMed ID: 31648333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.
    Delignat S; Repessé Y; Navarrete AM; Meslier Y; Gupta N; Christophe OD; Kaveri SV; Lacroix-Desmazes S
    Haemophilia; 2012 Mar; 18(2):248-54. PubMed ID: 22044692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of tolerance to factor VIII by transient co-administration with rapamycin.
    Moghimi B; Sack BK; Nayak S; Markusic DM; Mah CS; Herzog RW
    J Thromb Haemost; 2011 Aug; 9(8):1524-33. PubMed ID: 21585650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction of factor VIII-specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A.
    Madoiwa S; Yamauchi T; Kobayashi E; Hakamata Y; Dokai M; Makino N; Kashiwakura Y; Ishiwata A; Ohmori T; Mimuro J; Sakata Y
    J Thromb Haemost; 2009 May; 7(5):811-24. PubMed ID: 19220731
    [TBL] [Abstract][Full Text] [Related]  

  • 48. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
    Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
    Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Generation of factor VIII gene knockout mouse by tetraploid embryo complementation technology].
    Kuang Y; Wang J; Lu X; Lu S; Zhang L; Shen C; Fei J; Wang Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):1-6. PubMed ID: 20140858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
    Zhang AH; Skupsky J; Scott DW
    Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K; Shetty S
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody response to recombinant human coagulation factor VIII in a new rat model of severe hemophilia A.
    Lövgren KM; Søndergaard H; Skov S; Weldingh KN; Tranholm M; Wiinberg B
    J Thromb Haemost; 2016 Apr; 14(4):747-56. PubMed ID: 26784374
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term persistence of anti-factor VIII antibody-secreting cells in hemophilic mice after treatment with human factor VIII.
    Hausl C; Maier E; Schwarz HP; Ahmad RU; Turecek PL; Dorner F; Reipert BM
    Thromb Haemost; 2002 May; 87(5):840-5. PubMed ID: 12038787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.
    Krishnamoorthy S; Liu T; Drager D; Patarroyo-White S; Chhabra ES; Peters R; Josephson N; Lillicrap D; Blumberg RS; Pierce GF; Jiang H
    Cell Immunol; 2016 Mar; 301():30-9. PubMed ID: 26775174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.
    Delignat S; Peyron I; El Ghazaly M; V Kaveri S; Rohde J; Mueller F; Lacroix-Desmazes S
    Cell Immunol; 2018 Sep; 331():22-29. PubMed ID: 29751951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries.
    Schmidt A; Brettschneider K; Kahle J; Orlowski A; Becker-Peters K; Stichel D; Schulze J; Braner M; Tampé R; Schwabe D; Königs C
    Thromb Haemost; 2016 Jul; 116(1):32-41. PubMed ID: 27009573
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC; Scott DW
    Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A.
    Lai JD; Moorehead PC; Sponagle K; Steinitz KN; Reipert BM; Hough C; Lillicrap D
    Blood; 2016 Jun; 127(26):3439-49. PubMed ID: 27034428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
    Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer.
    Qian J; Burkly LC; Smith EP; Ferrant JL; Hoyer LW; Scott DW; Haudenschild CC
    Eur J Immunol; 2000 Sep; 30(9):2548-54. PubMed ID: 11009088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.